# Replimune Group 表示已與 FDA 達成協議，將重新提交其實驗性黑色素瘤藥物以申請批准。

*biotech · news · 2026-05-29 · STAT*

## Key points

- 世界衛生組織專家建議在 Bundibugyo 伊波拉疫情中使用一種抗病毒藥物和兩種單株抗體。
- Replimune Group 與 FDA 達成協議，在兩次被拒後重新提交其實驗性黑色素瘤藥物。
- Allogene 執行長 David Chang 將辭去其職務。
- Jeremy Levin 強調生物技術領域的科學進展正超越支援機構的發展速度。

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hiya. In this week’s episode of “The Readout LOUD,” biotech vet Jeremy Levin talks about how scientific progress is outpacing the institutions that support it. Also, WHO experts are recommending the use of an antiviral and two monoclonal antibodies in the response to the Bundibugyo Ebola outbreak, and Allogene CEO David Chang is stepping down. Advertisement The need-to-know this morning Replimune Group said it had reached an agreement with the FDA to resubmit its experimental melanoma drug for approval, after the therapy was twice rejected by the agency. Albert Bourla loves China

**Companies:** Replimune Group
**Countries:** China

[Read the full story on STAT](https://www.statnews.com/2026/05/29/biotech-news-allogene-ceo-david-chang-steps-down/)

---

Canonical: https://newsio.io/zh-TW/n/6471a4ba-0c15-47b2-8650-ccf7bd95a6ea/replimune-group-fda-bundibugyo
Summarized by Newsio from STAT. https://newsio.io/how-it-works